Skip to content

Study · Animal study (in vivo) · rat · 2020

12 results

Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons.

Chandrasekaran K, Choi J, Arvas MI, Salimian M, Singh S, Xu S, Gullapalli RP, Kristian T, Russell JW

International journal of molecular sciences26 May 2020Cited by 61 (Europe PMC)

PMID32466541 (opens in a new tab)PMCIDPMC7313029 (opens in a new tab)DOI10.3390/ijms21113756 (opens in a new tab)PepBankPUB-32466541
Download PDFPubMedAsk about this study
Jump to 12 results

Summary

Diabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD+ levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD+) levels to prevent dementia. We tested if the administration of the precursor of NAD+, nicotinamide mononucleotide (NMN), can prevent diabetes-induced memory deficits. Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ). After 3 months of diabetes, hippocampal NAD+ levels were decreased (p = 0.011). In vivo localized high-resolution proton magnetic resonance spectroscopy (MRS) of the hippocampus showed an increase in the levels of glucose (p p < 0.001), gamma aminobutyric acid (p = 0.018), myo-inositol (p = 0.018), and taurine (p N-acetyl aspartate (p = 0.002) and glutathione (p p p < 0.001) in the Diabetic rats. Diabetic rats showed hippocampal related memory deficits. Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months. NMN increased brain NAD+ levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione. NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control. In hippocampal protein extracts from Diabetic rats, SIRT1 and PGC-1α protein levels were decreased, and acetylation of proteins increased. NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins. Our results indicate that NMN increased brain NAD+, activated the SIRT1 pathway, preserved mitochondrial oxidative phosphorylation (OXPHOS) function, prevented neuronal loss, and preserved cognition in Diabetic rats.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, NMN increased brain NAD+ levels.

    In plain wordsIn rats with diabetes, NMN increased brain NAD+ levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseBrain NAD+
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN increased brain NAD+ levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione.
    2 context sentences
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, NMN normalized elevated hippocampal glutamate.

    In plain wordsIn rats with diabetes, NMN normalized elevated brain glutamate.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseHippocampal glutamate
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN increased brain NAD+ levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione.
    3 context sentences
    Summary · context
    In vivo localized high-resolution proton magnetic resonance spectroscopy (MRS) of the hippocampus showed an increase in the levels of glucose (p p < 0.001)
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, NMN normalized elevated hippocampal taurine.

    In plain wordsIn rats with diabetes, NMN normalized elevated brain taurine.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseHippocampal taurine
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN increased brain NAD+ levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione.
    2 context sentences
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, NMN normalized depleted hippocampal N-acetyl aspartate.

    In plain wordsIn rats with diabetes, NMN restored brain N-acetyl aspartate levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseHippocampal NAA
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN increased brain NAD+ levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione.
    2 context sentences
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, NMN normalized depleted hippocampal glutathione.

    In plain wordsIn rats with diabetes, NMN restored brain glutathione levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseHippocampal glutathione
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN increased brain NAD+ levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione.
    2 context sentences
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, NMN prevented CA1 neuron loss.

    In plain wordsIn rats with diabetes, NMN prevented loss of CA1 brain neurons.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseCA1 neuron loss
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control.
    2 context sentences
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, NMN rescued memory deficits.

    In plain wordsIn rats with diabetes, NMN reduced memory problems.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseMemory deficits
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control.
    2 context sentences
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, NMN had no significant effect on hyperglycemic control.

    In plain wordsIn rats with diabetes, NMN did not significantly improve blood sugar control.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeHyperglycemic control
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control.
    2 context sentences
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, NMN had no significant effect on lipidemic control.

    In plain wordsIn rats with diabetes, NMN did not significantly improve blood lipid control.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeLipidemic control
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control.
    2 context sentences
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, NMN prevented the decrease in hippocampal SIRT1 protein.

    In plain wordsIn rats with diabetes, NMN prevented a decrease in brain SIRT1 protein.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseSIRT1 protein
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins.
    2 context sentences
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, NMN prevented the decrease in hippocampal PGC-1α protein.

    In plain wordsIn rats with diabetes, NMN prevented a decrease in brain PGC-1α protein.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreasePGC-1α protein
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins.
    2 context sentences
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, NMN promoted hippocampal protein deacetylation.

    In plain wordsIn rats with diabetes, NMN increased removal of acetyl groups from brain proteins.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseProtein deacetylation
    Study

    ratn: not reported in source

    STZ-induced diabetes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    100 mg/kg on alternate days · intraperitoneal · 3 monthsAs given in this study (rat).

    Source sentences

    Summary
    NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins.
    2 context sentences
    Summary · context
    Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ).
    Summary · context
    Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.